Novelty Nobility extends its AGC manufacturing agreement
The companies are moving a candidate toward GMP manufacturing after cell-line development, with technology transfer planned between sites. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
- Published by
- GEN — Genetic Engineering & Biotechnology News
- Evidence type
- Industry
GEN reports: The companies are moving a candidate toward GMP manufacturing after cell-line development, with technology transfer planned between sites.
The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance. Consult the linked GEN report for the source organisation’s full announcement.
Let's engineer the next delivery breakthrough together
We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through GMP supply.
Prefer to talk it through? Book a 30-minute discovery call